BUZZ-Zenabis Global rises as JV gets approval for cannabis distribution Reuters 5/14/2021 Shares of pot producer up as much as 4.35% at C$0.12 Malta Medicines Authority grants ZENA s JV, ZenPharma, license to produce cannabis for medicinal and research purposes The license allows for commercial bulk imports into Malta from co s facility in Atholville and exports of finished medicinal cannabis products to European Union countries and UK Both HEXO Corp and co s combined product portfolio is expected to gain access to the European market, of which Germany is most prominent target Pot producer Materia won European Union certification for its Malta facility to produce and export cannabis flower across the continent on Thursday
Materia Announces Receipt of EU-GMP Certification in Malta
Materia Malta or the
EU GMP ) certification from the Malta Medicines Authority.
EU GMP is the global gold standard for pharmaceutical production and a requirement for medical cannabis in most European jurisdictions. This certification will enable Materia to begin processing and exporting medical cannabis flower from Malta into end markets across Europe, following the final post-certification steps in accordance with the licensure process. The Company also intends to apply for a licence amendment to process cannabis extracts imminently, leveraging the comprehensive preparatory work already completed. Becoming EU GMP certified in Malta represents our most significant milestone since we embarked on this project over two years ago, said Deepak Anand, CEO of Materia. We are excited to turn the engine on and showcase the full potential of a Malta-based cannabis processor to the industry, especially global partners seeking
Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Share:
OTTAWA, ON / ACCESSWIRE / April 28, 2021 /
Tetra Bio-Pharma Inc. (
Tetra or the
Company ) (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today that it has submitted a request to the Malta Medicines Authority for a Scientific Opinion on its investigational new drug (IND) QIXLEEF for Tetra s clinical trial programs. This request includes guidance on the REBORN2 trial to be performed in Europe. QIXLEEF is a botanical drug product with a fixed ratio of THC and CBD and is inhaled through a vaporizer. Based on the speed of onset of the pharmacodynamic effects of QIXLEEF, Tetra has positioned this inhaled IND as a potential therapy for the rapid relief of severe acute pain, such as breakthrough pain. Patients require fast relief when suffering from excruciating pain and we believe that the fast onset of QIXLEEF might be a viable alternative to opioids. We are seeking guidance from the Malta Medicines Authority on